The Administrative Core will provide logistic, administrative and budgetary support for all projects and cores supported by this P01 grant. The core will be directed by Dr. Steven Leach, PI for the overall grant, and staffed by Ms. Jennifer Holcomb, a supervisory-level administrative assistant with over fifteen years of experience here at Johns Hopkins. The Core will be responsible for fiscal management of overall program, and generating budgetary reports for each of the other Projects and Cores, in conjunction with research administrative personnel and financial managers from the Departments of Surgery, Oncology and Pathology, and also the Institute for Genetic Medicine. In addition, the Core will provide clerical support assisting investigators in the preparation of manuscripts, preparation of non-competing and competing renewals, and coordinating the distribution of plasmids, cell lines and transgenic animals requested by outside investigators. The Core will also be responsible for insuring that all investigators maintain strict compliance with relevant regulatory bodies here at Johns Hopkins, including the Animal Care and Use Committee, the Institutional Review Board, and the Radiation Safety Committee. The Core will also be responsible for establishing and maintaining the Johns Hopkins Pancreatic Cancer Program Project Grant Website, which will serve as a focal point for sharing information both among Program Participants, and also with the wider scientific community. This will be provided as a direct link from the already established Sol Goldman Pancreatic Cancer Research Center website (www.path.ihu.edu/pancreas). and will include both secure and non-secure portals for data and reagent sharing. Finally, the Core will broadly support communication and interaction between Program investigators, by coordinating the monthly Steering Committee meeting, and also arranging the monthly Sol Goldman Seminar Series, including assisting with travel arrangements, lodging and reimbursement for outside speakers. The Administrative Core will act as the primary liaision between Program Participants and the Internal and External Advisory Boards, and will schedule and provide logistical support for the Annual Program Retreat and Advisory Board meeting. The Core will be house in 200 sq. ft. of dedicated administrative space immediately adjoining the offices of Dr. Leach, Dr. Mendell and Dr. Parsons.
Pancreatic cancer represents one of the most deadly human malignancies, with five year survival rates of less than 5% and no change in this figure over the past four decades. By determining the genetic basis for this disease, our program will generate clinically relevant information that is likely to directly impact on strategies for chemoprevention, early detection and treatment.
|Park, J T; Johnson, N; Liu, S et al. (2015) Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene 34:2801-6|
|Rakheja, Dinesh; Chen, Kenneth S; Liu, Yangjian et al. (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802|
|Matthaei, Hanno; Wu, Jian; Dal Molin, Marco et al. (2014) GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol 38:360-3|
|Chivukula, Raghu R; Shi, Guanglu; Acharya, Asha et al. (2014) An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell 157:1104-16|
|McAllister, Florencia; Bailey, Jennifer M; Alsina, Janivette et al. (2014) Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25:621-37|
|Bailey, Jennifer M; Alsina, Janivette; Rasheed, Zeshaan A et al. (2014) DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 146:245-56|
|Krzeszinski, Jing Y; Wei, Wei; Huynh, HoangDinh et al. (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512:431-5|
|Patel, Kalpesh; Kern, Scott E (2013) "Selective cell death mediated by small conditional RNAs" is not selective. Cancer Biol Ther 14:693-6|
|Streppel, Mirte Mayke; Pai, Shweta; Campbell, Nathaniel R et al. (2013) MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 19:4067-78|
|Mendell, Joshua T; Olson, Eric N (2012) MicroRNAs in stress signaling and human disease. Cell 148:1172-87|
Showing the most recent 10 out of 35 publications